tiprankstipranks
Advertisement
Advertisement

IMNM Stock Latest News

Immunome price target lowered to $33 from $37 at Leerink
The FlyImmunome price target lowered to $33 from $37 at Leerink
6d ago
IMNM
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
PremiumRatings
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
7d ago
IMNM
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
PremiumRatings
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
8d ago
IMNM
Immunome reports Q1 EPS (48c), consensus (54c)
PremiumThe Fly
Immunome reports Q1 EPS (48c), consensus (54c)
9d ago
IMNM
Immunome announces submission of NDA for varegacestat in desmoid tumors
PremiumThe Fly
Immunome announces submission of NDA for varegacestat in desmoid tumors
22d ago
IMNM
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
PremiumThe FlyLeerink says Tubulis deal highlights value of ADC platforms like Sutro’s
1M ago
GILD
IMNM
Immunome: Best-in-Class Varegacestat Data and Deep ADC Pipeline Support Buy Rating and Favorable Risk‑Reward
Premium
Ratings
Immunome: Best-in-Class Varegacestat Data and Deep ADC Pipeline Support Buy Rating and Favorable Risk‑Reward
2M ago
IMNM
Immunome price target lowered to $30 from $32 at Lake Street
Premium
The Fly
Immunome price target lowered to $30 from $32 at Lake Street
3M ago
IMNM
Immunome price target raised to $36 from $33 at Craig-Hallum
PremiumThe Fly
Immunome price target raised to $36 from $33 at Craig-Hallum
3M ago
IMNM
Immunome price target lowered to $30 from $33 at Stephens
PremiumThe Fly
Immunome price target lowered to $30 from $33 at Stephens
3M ago
IMNM
Immunome price target raised to $39 from $35 at JPMorgan
PremiumThe Fly
Immunome price target raised to $39 from $35 at JPMorgan
3M ago
IMNM
Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
PremiumRatings
Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
3M ago
IMNM
Immunome reports FY25 EPS ($2.43), consensus ($2.21)
PremiumThe FlyImmunome reports FY25 EPS ($2.43), consensus ($2.21)
3M ago
IMNM
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
Premium
Ratings
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
3M ago
IMNM
Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
Premium
The Fly
Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
3M ago
ON
ADI
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
PremiumRatings
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
3M ago
IMNM
Immunome initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Immunome initiated with a Buy at H.C. Wainwright
3M ago
IMNM
Immunome Announces Follow-On Public Offering Pricing
PremiumCompany Announcements
Immunome Announces Follow-On Public Offering Pricing
5M ago
8K
IMNM
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
PremiumThe Fly
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
5M ago
PG
ABM
Immunome falls -7.2%
PremiumThe FlyImmunome falls -7.2%
5M ago
IMNM
Immunome 18.625M share Spot Secondary priced at $21.50
Premium
The Fly
Immunome 18.625M share Spot Secondary priced at $21.50
5M ago
IMNM
Immunome price target raised to $32 from $22 at Lake Street
Premium
The Fly
Immunome price target raised to $32 from $22 at Lake Street
5M ago
IMNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >